Synthetic Biologics to Webcast Microbiome Clinical Program Seminar

ROCKVILLE, Md., Dec. 7, 2015 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that its Microbiome Clinical Program Seminar will be webcast live at 9:00 a.m. EST on Thursday, December 10, 2015.

The Seminar will provide clinical updates on Synthetic Biologics' gut microbiome candidates – SYN-010 and SYN-004:

SYN-010 – Treatment of irritable bowel syndrome with constipation (IBS-C)

Topics: First and second Phase 2 clinical trials
Presenters:

• Mark Pimentel, MD, FRCP(C), Director, GI Motility Program, Professor of Medicine, Cedars-Sinai, Los Angeles, CA
• Marianela de la Portilla, MD, Principal Investigator, Genoma Research Group, Miami, FL

SYN-004 – Prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD)

Topics: Phase 1a and 1b, first and second Phase 2a and Phase 2b clinical trials
Presenters:

• Professor Mark H. Wilcox, MD, FRCPath, Consultant / Head of Microbiology, Leeds Teaching Hospitals NHS Trust, Professor of Medical Microbiology, University of Leeds, Lead on C. difficile Infection, Public Health England
• Eric Sicard, MD, Principal Investigator, Algorithme Pharma, Quebec, Canada

A live webcast of the presentations will begin on December 10, 2015 at 9:00 a.m. EST and is scheduled to conclude by 11:30 a.m. EST. The live webcast of the event will be available via the internet at: http://bit.ly/1QWBpYN. The archived webcast will be available at the same URL, http://bit.ly/1QWBpYN, for at least 90 days following the Seminar.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development include: (1) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and in collaboration with Intrexon Corporation (NYSE: XON), a preclinical stage monoclonal antibody for the prevention and treatment of Pertussis and discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Logo - http://photos.prnewswire.com/prnh/20130522/MM19465LOGO

SOURCE Synthetic Biologics, Inc.